Compounds as rearranged during transfection (RET) inhibitors

Patent metadata

Field	Value
Publication number	US-9879021-B2
Application number	US-201515509569-A
Country	US
Kind code	B2
Filing date	Sep 10, 2015
Priority date	Sep 10, 2014
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

First claim

What is claimed is:

1. A compound according to Formula (XIX), or a pharmaceutically acceptable salt thereof:

wherein:
A 1 is CH, A 2 is O, and A 3 is N; or A 1 is CH, A 2 is N, and A 3 is O; or A 1 is CH, A 2 is N, and A 3 is NR 15 ;
Z 1 , Z 2 , Z 3 , and Z 4 are each independently N, CH, or CR 6 , wherein 0, 1, or 2 of Z 1 , Z 2 , Z 3 , and Z 4 are N and 0, 1, or 2 of Z 1 , Z 2 , Z 3 , and Z 4 are CR 6 ;
R 2 is hydrogen, (C 1 -C 4 )alkyl, or (C 1 -C 4 )alkoxy;
R 3 is hydrogen, hydroxyl, (C 1 -C 4 )alkoxy, or (C 3 -C 6 )cycloalkoxy;
R 5 is hydrogen, hydroxyl, (C 1 -C 4 )alkoxy, or (C 3 -C 6 )cycloalkoxy;
each R 6 is independently selected from the group consisting of fluorine, chlorine, methyl, ethyl, difluoromethyl, cyclopropyl, methoxy, isopropoxy, and dimethylamino-;
R 14 is (C 1 -C 4 )alkyl or halo(C 1 -C 4 )alkyl; and
R 15 is hydrogen, methyl, ethyl, or phenyl.

2. The compound or pharmaceutically acceptable salt according to claim 1 , wherein A 1 is CH, A 2 is O, and A 3 is N.

3. The compound or pharmaceutically acceptable salt according to claim 1 , wherein two of Z 1 , Z 2 , Z 3 , and Z 4 are N and the other two are each independently CH or CR 6 .

4. The compound or pharmaceutically acceptable salt according to claim 1 , wherein R 2 is hydrogen.

5. The compound or pharmaceutically acceptable salt according to claim 1 , wherein R 3 is hydrogen or (C 1 -C 4 )alkoxy.

6. The compound or pharmaceutically acceptable salt according to claim 1 , wherein R 5 is hydrogen or (C 1 -C 4 )alkoxy.

7. The compound or pharmaceutically acceptable salt according to claim 1 , wherein:
A 1 is CH, A 2 is O, and A 3 is N;
two of Z 1 , Z 2 , Z 3 , and Z 4 are N and the other two are each independently CH or CR 6 ;
R 2 is hydrogen;
R 3 is hydrogen or (C 1 -C 4 )alkoxy;
R 5 is hydrogen or (C 1 -C 4 )alkoxy;
each R 6 is independently selected from the group consisting of fluorine, chlorine, methyl, ethyl, difluoromethyl, cyclopropyl, methoxy, isopropoxy, and dimethylamino-; and
R 14 is (C 1 -C 4 )alkyl or halo(C 1 -C 4 )alkyl.

8. The compound according to claim 1 which is:

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 which is:

10. The compound according to claim 9 in crystalline form.

11. The compound according to claim 10 , wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three diffraction angles, when measured using Cu K α radiation, selected from a group consisting of about 2.2, 4.9, 5.5, 5.7, 11.8, 11.9, 12.8, 12.9, 13.1, 14.3, 16.1, 16.6, 17.1, 17.2, 21.2, 21.3, 21.9, 22.0, 22.7, 22.8, 23.1, 25.3, and 25.4 degrees 2θ.

12. The compound according to claim 10 , wherein the crystalline form is characterized by an X-ray powder diffraction (XRPD) pattern comprising diffraction angles, when measured using Cu K α radiation, of about 5.7, 11.9, 12.9, 14.3, 16.1, and 23.1 degrees 2θ.

13. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 1 and a pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to claim 8 and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising the compound according to claim 9 and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising the compound according to claim 12 and a pharmaceutically acceptable excipient.

17. A method of treating irritable bowel syndrome comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to claim 1 .

18. A method of treating irritable bowel syndrome comprising administering to a human in need thereof an effective amount of the compound or pharmaceutically acceptable salt according to claim 8 .

19. A method of treating irritable bowel syndrome comprising administering to a human in need thereof an effective amount of the compound according to claim 9 .

20. A method of treating irritable bowel syndrome comprising administering to a human in need thereof an effective amount of the compound according to claim 12 .

Assignees

• Glaxosmithkline Ip Dev Ltd

Inventors

• Cheung Mui
• Demartino Michael P
• Eidam Hilary Schenck
• Guan Huiping Amy
• Qin Donghui
• Wu Chengde
• Gong Zhen
• Yang Haiying
• Yu Haiyu
• Zhang Zhiliu

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title